Combined oral contraceptives: optimal survey complex
Keywords:COC, PCOS, thyroid gland, hyperprolactinemia, САН, Cushing’s syndrome, acromegaly
Combined oral contraceptives (COCs) are effective drugs for contraception and the treatment of reproductive disorders in polycystic ovary syndrome (PCOS). The recommendation of using COCs according to the WHO guidelines “Medical eligibility criteria for using contraceptives” (5th edition, 2015) should begin with an assessment of the presence of risk factors that will help identify the group of women with high risks of complications from taking these drugs. This is an assessment of the risks
of thrombosis (venous and arterial) based on history, genetic testing data, age, smoking, medical status, the presence of several diseases and other risk factors: hypertension, migraine with aura, obesity, diabetes mellitus with vascular complications, severe diseases of the liver, blood, systemic lupus erythematosus, postpartum status. Based on these data, all women who are considered to be prescribing СOC will be ranked into four eligibility groups. This will determine for which women this method of contraception will be absolutely acceptable (category 1), and for whom it is unacceptable and other methods of contraception should be recommended (category 4).
To select these drugs as first-line treatment of reproductive disorders in PCOS, it is necessary to evaluate not only the presence of the above risk factors for the development of complications, but also to carry out a differential diagnosis of the main diseases that have a similar clinical picture, however, require specific treatment. This is a pathology of the thyroid gland, hyperprolactinemia, САН (21 hydroxylase deficiency), Cushing’s syndrome, acromegaly and a number of other, more rare diseases. Laboratory methods are used to screen and diagnose these diseases. Based on the guidelines of the specialized world organizations in Europe and America, algorithms for laboratory diagnosis of the main endocrinopathies are described. Particular attention is paid to factors influencing hormone levels, the rules for taking analysis and interpretation of the results.
- World Health Organization. Medical eligibility criteria for contraceptive use, 5th edition (2015). Available from: http://apps.who.int/iris/bitstream/handle/10665/181468/9789241549158_eng.pdf], last accessed Oct 30, 2018.
- Legro, R.S., Arslanian, S.A., Ehrmann, D.A., et al. “Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab 98.12 (2013): 4565–92.
- Сonway, G., Dewailly, D., Diamanti-Kandarakis, E., et al. “The polycystic ovary syndrome: a position statement from the European Society of Endocrinology.” Eur J Endocrinol 171.4 (2014): P1–29.
- Teede, H.J., Misso, M.L., Costello, M.F., et al. “International PCOS Network Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome.” Clin Endocrinol (Oxf) 89.3 (2018): 251–68.
- Lazarus, J., Brown, R.S., Daumerie, C., et al. “European Thyroid Association Guidelines for the Management of Subclinical Hypothyroidism in Pregnancy and in Children.” Eur Thyroid J 3.2 (2014): 76–94.
- Alexander, E.K., Pearce, E.N., Brent, G.A., et al. “Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum.” Thyroid 27.3 (2017): 315–89.
- Melmed, S., Casanueva, F.F., Hoffman, A.R., et al. “Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab 96.2 (2011): 273–88.
- Speiser, P.W., et al. “Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab 103.11 (2018) :1–46.
- Nieman, L.K., et al. “The diagnosis of Cuching’s syndrome: Аn Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab 93.5 (2008): 1526–40.
- Katznelson, L., Atkinson, J., Cook, D., et al. “American Association of clinical endocrinologists. Medical Guidelines for clinical practice for the diagnosis and treatment of acromegaly – 2011 Update.” Endocr Pract 17 Suppl. 4 (2011).
- Katznelson, L., Laws, E.R. Jr, Melmed, S., et al. “Acromegaly: An Endocrine Society Clinical Practice Guideline.” J Clin Endocrinol Metab 99.11 (2014): 3933–51.
- Dimaraki, E.V., Jaffe, C.A., DeMott-Friberg, R., et al. “Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up.” J Clin Endocrinol Metab 87 (2002): 3537–42.
How to Cite
Copyright (c) 2018 О. В. Рыкова
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.